Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Sapre, Nikhil ^a,b   Hong, Matthew K H ^a,b   Macintyre, Geoff ^a,c   Lewis, Heather ^b   Kowalczyk, Adam ^c   Costello, Anthony J ^a,b   Corcoran, Niall M ^a,b   Hovens, Christopher M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Australian Prostate Cancer Research Centre at Epworth   (Australia)

^c CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 16; MICRORNA 21; MICRORNA 222; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CANCER GRADING; CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CLINICAL ASSESSMENT; COHORT ANALYSIS; FOLLOW UP; GENE EXPRESSION; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME; URINALYSIS; BLOOD; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY; RISK; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899458809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091729     Document Type: Article

References (42)

1. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552.
2. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, et al. (1995) Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 274: 1445-1449.
3. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923.
4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, et al. (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161.
5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level, or = 4.0 ng per milliliter. N Engl J Med 350: 2239-2246.
6. Velonas VM, Woo HH, Remedios CG, Assinder SJ (2013) Current status of biomarkers for prostate cancer. Int J Mol Sci 14: 11034-11060.
7. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975-980. (Pubitemid 28445095)
8. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
9. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, et al. (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60: 753-766.
10. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, et al. (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106: 768-774.
11. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, et al. (2012) Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72: 1469-1477.
12. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, et al. (2011) Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77: 1265 e1269-1216.
13. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, et al. (2011) Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71: 550-560.
14. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, et al. (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741.
15. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9: 76.
16. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374. (Pubitemid 24037911)
17. Sherwin JC, Mirmilstein G, Pedersen J, Lawrentschuk N, Bolton D, et al. (2010) Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. J Urol 183: 1808-1814.
18. Daskivich TJ, Regan MM, Oh WK (2006) Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 176: 1927-1937. (Pubitemid 44633182)
19. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597. (Pubitemid 29211767)
20. Antonarakis ES, Chen Y, Elsamanoudi SI, et al (2010) Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int [Epub ahead of print].
21. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, et al. (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64.
22. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284. (Pubitemid 33000466)
23. Benes V, Castoldi M (2010) Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50: 244-249.
24. Molina-Pinelo S, Suarez R, Pastor MD, Nogal A, Marquez-Martin E, et al. (2012) Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers 32: 221-230.
25. Mees ST, Schleicher C, Mardin WA, Senninger N, Colombo-Benkmann M, et al. (2011) Analyzing miRNAs in ductal adenocarcinomas of the pancreas. J Surg Res 169: 241-246.
26. Lu Q, Zhang J, Allison R, Gay H, Yang WX, et al. (2009) Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate 69: 411-418.
27. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, et al. (2009) Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 100: 1603-1607.
28. Payne SR, Serth J, Schostak M, Kamradt J, Strauss A, et al. (2009) DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 69: 1257-1269.
29. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, et al. (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13: 1720-1725. (Pubitemid 46952937)
30. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, et al. (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15; discussion 15-16.
31. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
32. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135. (Pubitemid 47037493)
33. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261. (Pubitemid 43271657)
34. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, et al. (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671-681.
35. Coppola V, De Maria R, Bonci D (2010) MicroRNAs and prostate cancer. Endocr Relat Cancer 17: F1-17.
36. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, et al. (2012) A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72: 1443-1452.
37. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, et al. (2011) Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32: 583-588.
38. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, et al. (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608-616.
39. Sapre N, Selth LA (2013) Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. Prostate Cancer 2013: 539680.
40. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, et al. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975-5979. (Pubitemid 30004960)
41. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, et al. (2012) The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 109: 360-366.
42. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, et al. (2011) A multicenter study of [22]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185: 1650-1655.